The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Open accessAbstract
Activation of the tyrosine kinase of the c-src gene product, pp60c-src, has been shown to occur in nearly every primary colorectal carcinoma, and is found as early as in polyps of high malignant potential. However, no studies have addressed potential pp60c-src changes which occur during progression. To examine this question, we have studied kinase activity and protein levels in 7 colonic polyps, 19 primary lesions, and 19 liver metastases relative to normal colonic mucosa. Significant increases in tyrosine kinase activity were seen as early as in colonic polyps of high malignant potential. Further increases were observed in activity and level in primary tumors. However, the greatest increases in activity and protein levels were observed in liver metastases. Additionally, six metastatic lesions were obtained in which synchronous primary tumor was resected. In each of these liver metastases, pp60c-src activity and level were significantly increased relative to the corresponding primary tumor, as well as to normal colonic mucosa. Our results demonstrate that progression of colon primary tumors to liver metastases correlates with increased pp60c-src kinase activity and protein level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the SRC activation signature score was significantly associated with metastasis and primary tumor stage I-IV progression (Fig. 2g,h), in agreement with previous studies in CRC [37–40].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Talamonti et al reported increased activity and expression of SFKs in progressive stages of human colorectal cancer, suggesting that colon cancer progression may be dependent on increased SFK protein level and subsequent activity (Talamonti et al., 1993).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Talamonti et al., 1993
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Higher expression and activity of SRC has been documented in primary colon tumors compared with benign polyps or non-transformed colonic mucosa, and increased activity is observed in progressive stages of CRC [23–26].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [25]
In the citing paper
“However, c-Src seems to experience a robust increase in expression and activity in CRC liver metastases compared with metastases derived from other tumors types [11, 12]”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [12]
In the citing paper
“C-src, though, seems to have a robust increase regarding expression and activity in CRC liver metastases compared to those derived from other tumors types.3,11,13”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“In CRC cell lines and primary tumors, both c-src kinase activity and protein expression levels have been found elevated compared either to normal colonic mucosal cells and fibroblasts or normal adjacent tissue, respectively.3,10,11”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“Increased specific activity and expression levels have been detected in colonic polyps of high malignant potential and severe dysplasia.11,12”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,311
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Identification and characterization of the familial adenomatous polyposis coli gene
Groden, J. L., Thliveris, A. T., Samowitz, W. S., Carlson, M. L., Gelbert, L. M., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L. N., Robertson, M. A., et al. (1991) · Cell · doi:10.1016/0092-8674(81)90021-0 · Cited by 2,794
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler‐Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,701
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,331
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097
Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients
Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., Hedge, P., et al. (1991) · Science · doi:10.1126/science.1651563 · Cited by 1,891
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., BOOM, J. H. V., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–406 of 406
BindingDB (2010) · UC San Diego · doi:10.7270/q2n879k8
Development of novel therapies for colorectal carcinoma using dietary indoles
Brookes, A. (2014) · Leicester Research Archive (University of Leicester)
Metadata
- Authors
- Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Talamonti, M S
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 53-60
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC329994
- OpenAlex
- W2030565228
- Cited by
- 399
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 14 · 2016: 8 · 2015: 13 · 2014: 11 · 2013: 17 · 2012: 24
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca053167-06)
- National Cancer Institute (CA09599, CA53167, T32CA009599)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, tyrosine kinase activity, colorectal cancer, tumor progression, colonic polyps, liver metastasis, synchronous primary tumors, oncogene activation
- MeSH terms
- Adenocarcinoma, Adenoma, Antigen-Antibody Complex, Colonic Neoplasms, Colonic Polyps, Humans, Intestinal Mucosa, Liver Neoplasms, Neoplasm Metastasis, Neoplasm Staging, Phosphopyruvate Hydratase, Phosphorylation, Protein Kinases, Protein-Tyrosine Kinases, Rectal Neoplasms, Reference Values, Immunoblotting, Proto-Oncogene Proteins pp60(c-src)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
